Eledon Pharmaceuticals, Inc. Common Stock
Veridion Score
Composite trend over time
Why is ELDN moving today?
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ELDN.
ELDN insider activity
Eledon Pharmaceuticals, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for ELDN.
ELDN contract awards, year to date.
Public federal awards linked to this ticker.
ELDN lobbying filings, year to date.
Registered lobbying filings matched to Eledon Pharmaceuticals, Inc. Common Stock.